238 related articles for article (PubMed ID: 35941192)
1. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.
van der Stegen SJC; Lindenbergh PL; Petrovic RM; Xie H; Diop MP; Alexeeva V; Shi Y; Mansilla-Soto J; Hamieh M; Eyquem J; Cabriolu A; Wang X; Abujarour R; Lee T; Clarke R; Valamehr B; Themeli M; Riviere I; Sadelain M
Nat Biomed Eng; 2022 Nov; 6(11):1284-1297. PubMed ID: 35941192
[TBL] [Abstract][Full Text] [Related]
2. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
4. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells.
Ueda T; Shiina S; Iriguchi S; Terakura S; Kawai Y; Kabai R; Sakamoto S; Watanabe A; Ohara K; Wang B; Xu H; Minagawa A; Hotta A; Woltjen K; Uemura Y; Kodama Y; Seno H; Nakatsura T; Tamada K; Kaneko S
Nat Biomed Eng; 2023 Jan; 7(1):24-37. PubMed ID: 36509913
[TBL] [Abstract][Full Text] [Related]
7. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
9. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
10. Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.
Minagawa A; Kaneko S
Methods Mol Biol; 2019; 2048():81-84. PubMed ID: 31396932
[TBL] [Abstract][Full Text] [Related]
11. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia.
Abdin SM; Paasch D; Kloos A; Oliveira MC; Jang MS; Ackermann M; Stamopoulou A; Mroch PJ; Falk CS; von Kaisenberg CS; Schambach A; Heuser M; Moritz T; Hansen G; Morgan M; Lachmann N
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135346
[TBL] [Abstract][Full Text] [Related]
12. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Minagawa A; Yoshikawa T; Yasukawa M; Hotta A; Kunitomo M; Iriguchi S; Takiguchi M; Kassai Y; Imai E; Yasui Y; Kawai Y; Zhang R; Uemura Y; Miyoshi H; Nakanishi M; Watanabe A; Hayashi A; Kawana K; Fujii T; Nakatsura T; Kaneko S
Cell Stem Cell; 2018 Dec; 23(6):850-858.e4. PubMed ID: 30449714
[TBL] [Abstract][Full Text] [Related]
13. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
14. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
Michaux A; Mauën S; Breman E; Dheur MS; Twyffels L; Saerens L; Jacques-Hespel C; Gauthy E; Agaugué S; Gilham DE; Sotiropoulou PA
J Immunother; 2022 Apr; 45(3):150-161. PubMed ID: 35191428
[TBL] [Abstract][Full Text] [Related]
15. When CAR Meets Stem Cells.
Lee JM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
[TBL] [Abstract][Full Text] [Related]
16. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z; Luo F; Chu Y
Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
[TBL] [Abstract][Full Text] [Related]
17. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
18. CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma.
Rowan AG; Ponnusamy K; Ren H; Taylor GP; Cook LBM; Karadimitris A
Front Immunol; 2023; 14():1118681. PubMed ID: 36936927
[TBL] [Abstract][Full Text] [Related]
19. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
20. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
